Pherine

Vistagen Announces Closing of Pherin Pharmaceuticals Acquisition

Retrieved on: 
Thursday, February 2, 2023
Biotechnology, Pharmaceutical, Health, Mental Health, Additive effect, DSM-IV codes, Drug development, PH94B, Acquisition, SAD, PH10, Depression, Mixed anxiety–depressive disorder, CNS, Anxiety, Social anxiety disorder, MDD, Ajda, Migraine, Central nervous system, Cognition, Hot, Pharmaceutical industry, Pherine

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced the closing of its acquisition of Pherin Pharmaceuticals, Inc., a privately held drug development company focused on neuropsychiatric and neuroendocrine conditions (Pherin).

Key Points: 
  • Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced the closing of its acquisition of Pherin Pharmaceuticals, Inc., a privately held drug development company focused on neuropsychiatric and neuroendocrine conditions (Pherin).
  • Vistagen’s acquisition of Pherin eliminates all future royalty payment obligations related to its five pherine nasal spray drug candidates.
  • “This acquisition is another important step in our plan to develop and commercialize PH94B and PH10 as innovative treatments for millions of individuals struggling with anxiety and depression disorders,” stated Shawn Singh, Chief Executive Officer of Vistagen.
  • This acquisition significantly improves the potential future commercial profile of each drug candidate.”
    Additional details regarding the closing of Vistagen’ acquisition of Pherin can be found in the Company’s Current Report on Form 8-K, filed with the U.S. Securities and Exchange Commission today and available in the Investors section of Vistagen’s website.

Vistagen to Acquire Pherin Pharmaceuticals

Retrieved on: 
Wednesday, December 21, 2022
Biotechnology, Neurology, Health, Pharmaceutical, Clinical Trials, Migraine, Anxiety, SAD, Flash, Disorder, Central nervous system, MDD, PH94B, Depression, CNS, Acquisition, Patient, Ajda, Cognition, Social anxiety disorder, PH10, Pharmaceutical industry, Pherine

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, and Pherin Pharmaceuticals, Inc., a clinical-stage drug development company focused on the discovery and development of investigational pherine compounds for treatment of neuropsychiatric and neuroendocrine conditions (Pherin), today announced that the companies have entered into a definitive agreement under which Vistagen will acquire Pherin for approximately 12.4 million shares of Vistagen common stock and a nominal amount of cash.

Key Points: 
  • Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, and Pherin Pharmaceuticals, Inc., a clinical-stage drug development company focused on the discovery and development of investigational pherine compounds for treatment of neuropsychiatric and neuroendocrine conditions (Pherin), today announced that the companies have entered into a definitive agreement under which Vistagen will acquire Pherin for approximately 12.4 million shares of Vistagen common stock and a nominal amount of cash.
  • Upon closing of the acquisition, which is subject to certain customary closing conditions, Vistagen will acquire Pherin’s entire pherine pipeline, resulting in Vistagen gaining full ownership of intellectual property rights to its two most advanced drug candidates, PH94B, currently in Phase 3 development for social anxiety disorder (SAD) and Phase 2 development for adjustment disorder with anxiety (AjDA), and PH10, in clinical development for major depressive disorder (MDD).
  • Vistagen will also expand its pipeline with three new early clinical-stage pherine product candidates: PH15 for cognition improvement; PH80 for migraine and hot flashes; and PH284 for appetite-related disorders.
  • “Since 2018, we have observed the experienced Vistagen team working diligently to advance all aspects of development for PH94B and PH10.

VistaGen’s PH10 Nasal Spray Demonstrates Different Mechanism of Action from Benzodiazepines in Preclinical Study

Retrieved on: 
Thursday, March 11, 2021
Branches of biology, Cell signaling, GABAA receptor positive allosteric modulators, Pherine, Steroids, PH10, Hypnotics, Psychoactive drugs, Benzodiazepine, Antidepressant, GABA receptor

Using in vitro patch clamp electrophysiology, PH10 had no agonist or antagonist effects on GABA receptors.

Key Points: 
  • Using in vitro patch clamp electrophysiology, PH10 had no agonist or antagonist effects on GABA receptors.
  • In September 2020, the U.S. Food and Drug Administration (FDA) released a Drug Safety Communication (DSC) detailing the risks associated with use of benzodiazepines.
  • PH10 is a new generation antidepressant with a mechanism of action that is designed to be fundamentally different from all current FDA-approved antidepressants.
  • PH10 is a Phase 2 investigational pherine nasal spray designed to have rapid-onset effects and therapeutic potential in several neuropsychiatric indications involving depression.

VistaGen Announces Publication in CNS Spectrums Detailing Proposed Mechanism of Action of Its Investigational Neuroactive Nasal Sprays for Anxiety and Depression Disorders

Retrieved on: 
Wednesday, December 30, 2020
Psychiatry, Branches of biology, Psychology, Psychiatric diagnosis, PH10, Abnormal psychology, 4-Androstadienol, Anxiety, Neurosteroid, Mental disorder, Pherine

PH94B and PH10 were discovered and developed for their specific therapeutic potential to treat anxiety and depression disorders, representing a new class of neuropharmaceuticals, said Dr. Monti.

Key Points: 
  • PH94B and PH10 were discovered and developed for their specific therapeutic potential to treat anxiety and depression disorders, representing a new class of neuropharmaceuticals, said Dr. Monti.
  • Bringing hope to individuals who continue to suffer from anxiety and depression is at the core of VistaGens mission, added Shawn Singh, VistaGens Chief Executive Officer.
  • CNS Spectrums, 1-7. doi:10.1017/S109285292000190X
    PH94B is an innovative odorless investigational synthetic neuroactive steroid nasal spray with therapeutic potential in multiple mental health disorders involving anxiety or phobia and is designed to have a rapid-onset.
  • VistaGen is currently preparing PH94B for Phase 3 development as a potential acute treatment of anxiety in adults with SAD.

VistaGen Announces Korean Intellectual Property Office Decision to Grant PH10 Patent for Treatment of Depression

Retrieved on: 
Thursday, December 10, 2020
PH10, Antidepressants, Drugs, Medical research, Major depressive disorder, Health sciences, Pherine, NMDA receptor antagonists

With counterpart patents already issued in the U.S., Greater China, Europe and Japan, this patent enhances our patent protection for PH10 and is a key component of our global commercial protection strategy for PH10," stated Shawn K. Singh, Chief Executive Officer of VistaGen.

Key Points: 
  • With counterpart patents already issued in the U.S., Greater China, Europe and Japan, this patent enhances our patent protection for PH10 and is a key component of our global commercial protection strategy for PH10," stated Shawn K. Singh, Chief Executive Officer of VistaGen.
  • We believe PH10 has the potential to transform the treatment landscape for individuals with MDD in global depression markets, and we believe this patent will help protect and propel global development," continued Mr. Singh.
  • PH10 is an innovative odorless investigational synthetic neuroactive nasal spray designed to have rapid-onset and therapeutic potential in several neuropsychiatric indications involving depression, including MDD and suicidal ideation.
  • Following successfully completed exploratory Phase 2A clinical development, VistaGen is preparing for Phase 2B clinical development of PH10 as a potential stand-alone, rapid-onset treatment for MDD.

VistaGen Therapeutics Expands R&D Team with Appointment of Louis Monti, M.D., Ph.D., Pioneer in the Development of Neuroactive Steroids known as Pherines as Potential Treatments for Anxiety and Depression Disorders, as Vice President, Translational Medici

Retrieved on: 
Tuesday, December 1, 2020
Psychiatric diagnosis, Pherine, Steroids, 4-Androstadienol, Anxiety, Major depressive disorder, Neuroscience

We are excited that he has now joined us as a full-time member of our R&D team."

Key Points: 
  • We are excited that he has now joined us as a full-time member of our R&D team."
  • Dr. Monti commented, "Driving research of neuroactive pherines to develop innovative medicines with the potential to lift the burdens of anxiety and depression has been a passion throughout my career.
  • I am truly pleased to join a team that shares that sense of commitment and purpose.
  • VistaGen is currently preparing PH94B for Phase 3 development as a potential acute treatment of anxiety in adults with SAD.